BNTC · Benitec Biopharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $59.0K | $102.0K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $18.33M | $15.61M | $12.77M | $11.27M | $7.02M | $3.00M |
| SG&A | $23.43M | $6.99M | $6.38M | $6.65M | $6.51M | $5.57M |
| Total Operating Expenses | $41.77M | $22.49M | $19.16M | $17.93M | $13.65M | $8.38M |
| D&A | $66.0K | $87.0K | $136.0K | $167.0K | $231.0K | $190.0K |
| Operating Income | ($41.77M) | ($22.49M) | ($19.08M) | ($17.85M) | ($13.60M) | ($8.28M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($37.92M) | ($21.75M) | ($19.56M) | ($18.21M) | ($13.88M) | ($8.27M) |
| EPS - Basic | ($1.05) | ($5.51) | ($14.12) | ($54.91) | - | - |
| EPS - Diluted | ($1.05) | ($5.51) | ($14.12) | ($54.91) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $97.74M | $50.87M | $2.48M | $4.06M | $19.77M | $11.88M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $201.0K | $1.35M | $1.14M | $422.0K | $274.0K | $1.47M |
| Current Assets | $98.52M | $51.67M | $3.73M | $4.82M | $20.61M | $18.76M |
| Total Assets | $99.59M | $52.21M | $4.46M | $5.97M | $21.38M | $19.23M |
| Current Liabilities | $1.80M | $4.92M | $3.98M | $2.53M | $1.37M | $2.64M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $2.30M | $4.96M | $4.26M | $3.09M | $1.37M | $2.64M |
| Stockholders' Equity | $97.30M | $47.25M | $202.0K | $2.88M | $20.01M | $13.84M |
| Retained Earnings | ($228.18M) | ($190.26M) | ($167.89M) | ($148.33M) | ($130.12M) | ($108.87M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($23.59M) | ($19.40M) | ($18.01M) | ($15.90M) | ($12.83M) | ($7.54M) |
| Investing Cash Flow | ($18.0K) | ($179.0K) | ($1.0K) | ($13.0K) | ($221.0K) | ($94.0K) |
| Financing Cash Flow | $70.48M | $68.03M | $16.02M | - | $22.52M | $1.77M |
| CapEx | $18.0K | $179.0K | $1.0K | $13.0K | $221.0K | $95.0K |
| Free Cash Flow | ($23.61M) | ($19.58M) | ($18.01M) | ($15.91M) | ($13.05M) | ($7.63M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -23044.1% | -8118.6% |
| EBITDA margin | - | - | - | - | -22652.5% | -7932.4% |
| Net margin | - | - | - | - | -23528.8% | -8111.8% |
| Free cash flow margin | - | - | - | - | -22123.7% | -7480.4% |
| FCF / Net income | 0.62 | 0.90 | 0.92 | 0.87 | 0.94 | 0.92 |
| R&D / Revenue | - | - | - | - | 11898.3% | 2942.2% |
| SG&A / Revenue | - | - | - | - | 11037.3% | 5457.8% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -38.1% | -41.7% | -438.2% | -304.8% | -64.9% | -43.0% |
| Return on equity | -39.0% | -46.0% | -9684.2% | -631.8% | -69.4% | -59.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 7.10 |
| Quick ratio | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 7.10 |
| Cash ratio | 54.24 | 10.33 | 0.62 | 1.60 | 14.44 | 4.50 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.02 | 1.11 | 22.10 | 2.07 | 1.07 | 1.39 |
| Liabilities / Assets | 0.02 | 0.10 | 0.95 | 0.52 | 0.06 | 0.14 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | 0.00 | 0.01 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 4.4x | 0.6x | 27.9x | 29.4x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | -42.2% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -85.7% | -17.9% | -6.9% | -31.3% | -64.2% | - |
| Net income growth (YoY) | -74.3% | -11.2% | -7.4% | -31.2% | -67.8% | - |
| EPS growth (YoY) | 80.9% | 61.0% | 74.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -20.5% | -8.7% | -13.2% | -21.9% | -71.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 105.9% | 23290.1% | -93.0% | -85.6% | 44.5% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Benitec Biopharma Inc. against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Jun 1, 2018 | $0.7650 |